Devices and methods for vascular navigation, assessment and/or diagnosis are disclosed where a location detection system generally includes an elongate body defining a lumen at least partially along a length of the elongate body. One or more sensors are positioned near or at a distal tip of the elongate body and one or more openings are defined along the elongate body in proximity to the one or more sensors. The one or more openings are configured to control a boundary distance between the one or more sensors and a fluid with a parameter of a known initial value when emitted from the one or more openings. A controller is in communication with the one or more sensors and is configured to track a change in the parameter relating to concentration over the one or more sensors and determine a position of the one or more sensors within a body.

Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and/or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and/or degraded within the GI tract.

A system and method are described for controlling a vehicle interior environmental condition. A biometric sensor senses a biometric condition of a vehicle seat occupant and generates a sensed biometric condition value. A controller receives the sensed biometric condition value, a sensed interior environmental condition value, and a sensed exterior environmental condition value. Each of multiple exterior environmental condition values has an associated biometric condition value defined as optimal for the vehicle occupant. The controller determines the optimal biometric condition value associated with the sensed exterior environmental condition value, compares the optimal biometric condition value to the sensed biometric condition value, and in response to a difference between the optimal biometric condition value and the sensed biometric condition value, generates a control signal to control an actuator to control the controllable interior environmental condition to reduce the difference between sensed biometric condition value and the optimal biometric condition value.

Provided herein are methods for in-vivo assessment of intraventricular flow shear stress, risk of hemolysis, also the location and extent of blood flow stasis regions and inside a cardiac chamber or blood vessel. Also provided herein are systems for performing such methods. Also provided herein are methods for assessing hemolysis and/or thrombosis risk in patients implanted with an LVAD. LVAD positioning and/or speed may be adjusted based on the results obtained by using methods described herein, and the risk for hemolysis and/or thrombosis can be minimized.

The invention disclosed herein relates to improvements in the collection personal health data. It further relates to a Personal Health Monitor (PHM), which may be a Personal Hand Held Monitor (PHHM), that incorporates a Signal Acquisition Device (SAD) and a processor with its attendant screen and other peripherals. The SAD is adapted to acquire signals which can be used to derive one or more measurements of parameters related to the health of a user. The computing and other facilities of the PHM with which the SAD is integrated are adapted to control and analyse signals received from the SAD. The personal health data collected by the SAD may include data related to one or more of blood pressure, pulse rate, blood oxygen level (SpO.sub.2), body temperature, respiration rate, ECG, cardiac output, heart function timing, arterial stiffness, tissue stiffness, hydration, blood viscosity, blood pressure variability, the concentration of constituents of the blood such as glucose or alcohol and the identity of the user.

A blood-viscosity measurement method uses a collection tube includes a bottomed tube having an opening at one end in a length direction and a bottom at the other end in the length direction. A sealing plug includes a sealing part fitted in the opening of the bottomed tube in a hermetically sealed state, a cap part, and a thin connecting part. The sealing part includes a vertically penetrated insertion hole and fitted in the opening of the bottomed tube. The method includes collecting blood using a negative pressure state of the inner space, applying an external force to the cap portion to break the connecting part and removing the cap part to expose the insertion hole at an upper surface of the sealing part, and obtaining blood viscosity by causing a viscosity-measurement falling body to fall from the insertion hole, and measuring a fall terminal velocity of the falling body.

The invention relates to a system for challenging the pericardial space, to provide an indication of the risk of cardiac tamponade in a patient, as well as methods for diagnosis of, and determination of the extent of, a tamponade, and treating a patient in whom there is a detected cardiac tamponade.

Provided herein are methods for in-vivo assessment of intraventricular flow shear stress, risk of hemolysis, also the location and extent of blood flow stasis regions and inside a cardiac chamber or blood vessel. Also provided herein are systems for performing such methods. Also provided herein are methods for assessing hemolysis and/or thrombosis risk in patients implanted with an LVAD. LVAD positioning and/or speed may be adjusted based on the results obtained by using methods described herein, and the risk for hemolysis and/or thrombosis can be minimized.

An identification device including a generation unit and an information identification unit. The generation unit generates factor information relating to pulse-wave information with respect to an identification target in accordance with biological model information representing a relevance between pulse-wave information representing a pulse wave and the factor information representing a factor of pulse wave. The information identification unit selects certain list information satisfying a predetermined determination criterion of the factor information generated by the generation unit out of list information associating the factor information generated based on the pulse-wave information representing a pulse wave of a biological subject to be an identification target with identification information for identifying the biological subject, and identifies the identification information in the selected certain list information.

Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and/or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and/or degraded within the GI tract.